Mati Therapeutics Inc. is an early-stage company addressing the massive glaucoma market. Founder and CEO Robert Butchofsky discussed the main challenges to all glaucoma-focused sustained drug delivery platforms, and described Mati’s solution: the Evolute minimally invasive, sustained-delivery platform, which uses punctum plugs to deliver drugs for ocular diseases, particularly glaucoma. Evolute will enter a Phase III trial in 2015 for delivering a PGA drug.
Robert Butchofsky is the Founder and CEO of Mati Therapeutics. Headquartered in Austin, Texas, Mati is developing a non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma.